Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3
Open Access

A review of electromagnetic frequency modulation, with a focus on eMedica as a therapeutic approach for Parkinson's disease, that goes beyond pharmaceutical treatments.

Hemant Rohera [1], Dr Gauri Makarand Apte [2], Dr Makarand Vishwas Apte [3], Dr Deepak Nagpal

[1] Director, Research and development, Rohera Healthcare Technologies, Pune, Maharashtra, India
[2] Associate Professor in Physiology MIMER Medical College & Dr BSTR Hospital, Talegaon Dabhade, Pune.
[3] Associate Professor in Anatomy MIMER Medical College & Dr BSTR Hospital, Talegaon Dabhade, Pune
[4] Ex-Dean, Professor and Head, Department of Oral Pathology and Microbiology Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur, Mahrarashtra, India

Corresponding author:
Dr Deepak Nagpal
Email: deepaknagpal2013@gmail.com

Cite this paper as: Hemant Rohera, Dr Gauri Makarand Apte, Dr Makarand Vishwas Apte, Dr Deepak Nagpal (2024) A review of electromagnetic frequency modulation, with a focus on eMedica as a therapeutic approach for Parkinson's disease, that goes beyond pharmaceutical treatments. *Frontiers in Health Informatics, 13* (3), 10720-10726

Abstract:

Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by motor and non-motor symptoms that significantly impact the quality of life of those affected. Current management strategies encompass pharmacological treatments, physiotherapy, and lifestyle modifications. However, these methods often yield limited benefits and do not address the underlying disease mechanisms. This review explores the potential of the Electromagnetic Frequency Modulation device, eMedica, as an innovative therapeutic strategy for enhanced management of PD. Through a review of existing literature on electromagnetic therapy, neuroprotection, and the specific applications of eMedica, this paper proposes a multidisciplinary approach that leverages new technology to improve PD outcomes.

Keywords: *Parkinson's Disease, neurodegenerative disorder, pharmacological, physiotherapy, eMedica, neuroprotection*

Introduction

Parkinson's Disease affects approximately 1% of the population over the age of 60 and is characterized by motor symptoms such as tremors, rigidity, and bradykinesia, alongside non-motor symptoms including anxiety, depression, and cognitive decline [1]. The pathophysiology of PD involves the

degeneration of dopaminergic neurons in the substantia nigra, leading to reduced dopamine levels and impaired neurotransmission [2-4]. Current treatment modalities, primarily focused on pharmacotherapy with dopaminergic agents, often encounter limitations regarding efficacy and side effects, necessitating ongoing research into alternative approaches.

Electromagnetic field therapy has emerged as a non-invasive method that may provide adjunctive benefits in managing neuronal disorders. The eMedica device utilizes frequency modulation to deliver electromagnetic signals that could potentially modulate brain activity, promote neuroprotection, and ameliorate motor symptoms in PD patients. This paper assesses the therapeutic potential of eMedica as a supplemental strategy in PD management.

Electromagnetic frequency modulation has been explored as a potential therapeutic strategy for Parkinson's disease. Vadalà M etal [6] discusses the mechanisms and therapeutic applications of electromagnetic therapy, including transcranial magnetic stimulation and pulsed electromagnetic field therapy, to alleviate motor and non-motor deficits in Parkinson's disease.
Sandyk R in his study [7] reports improved olfactory function in fully medicated Parkinsonian patients following the therapeutic transcranial application of AC pulsed electromagnetic fields.
More recent research has focused on the epigenetic basis of the brain's response to electromagnetic therapy in Parkinson's disease patients. Consales C etal [8] discusses how modulations of epigenetic machinery have been included among the key effects of electromagnetic stimulation in their literature review.

In terms of specific treatment outcomes, Hosseini SM etal in their systemic review and metaanalysis compares the effectiveness of electric and magnetic field therapies for reducing tremors in Parkinson's disease patients. The review suggests that electromagnetic therapies may modulate the stretch reflex through electrical nerve stimulation, modulate tremor frequency by nerve stimulation, and affect the peripheral reflex mechanism by electrical stimulation [9].

Magnetic field therapy has also been specifically investigated for its potential in treating Parkinson's disease. Sandyk R etal reported the application of weak magnetic fields in a Parkinsonian patient with severe levodopa-induced dyskinesias, resulting in improved motor function [10].

More recent research has explored the use of static magnetic fields and magnetic nanoparticles in the treatment of Parkinson's disease. Wang Z in their study found that static magnetic fields in the tenths of Tesla range can reproduce cellular effects of the Parkinson's disease drug candidate ZM241385 [11]. Dhillon K in their study discusses the use of magnetic field gradients and magnetic nanoparticles to control neuronal outgrowth from the substantia nigra towards targeted areas in the brain, a potential approach for stem cell therapies in Parkinson's disease [12].

Overall, while the research is still in its early stages, electromagnetic frequency modulation, including both electric and magnetic field therapies, shows promise as a potential therapeutic strategy for alleviating symptoms and improving quality of life in Parkinson's disease patients.

Current Management Strategies for Parkinson's disease

Pharmacological Approaches

The primary pharmacological intervention for PD includes levodopa, which is converted to dopamine in the brain. While effective, long-term use can result in motor fluctuations and dyskinesias [5-10]. Recent advancements also include dopamine agonists, monoamine oxidase-B inhibitors, and catechol-O-methyltransferase inhibitors, yet these treatments often fail to provide comprehensive relief from motor and non-motor symptoms [6- 7,11-13].

Non-Pharmacological Strategies

Physical therapy, occupational therapy, and speech therapy form important components of PD management and focus on improving mobility, daily function, and communication respectively. Exercise interventions, including aerobic and resistance training, have been shown to enhance physical function and may possess neuroprotective properties [15].

The Electromagnetic Frequency Modulation Device, eMedica

Overview of Electromagnetic Therapy

Electromagnetic therapy has garnered attention for its potential effects on cellular activity, promoting healing and regeneration [1-4]. Studies have highlighted the ability of low-frequency electromagnetic fields to modulate voltage-gated calcium channels, enhance neuroplasticity, and promote cellular repair mechanisms [16].

Mechanism of Action

eMedica employs a frequency modulation mechanism designed to deliver specifically tuned electromagnetic signals. These signals may influence neuronal excitability, enhance synaptic transmission, and potentially protect neurons from oxidative stress and apoptosis associated with PD [17-23].

Clinical Applications and Studies

Preliminary studies using electromagnetic therapy in Parkinson's Disease have shown promise in reducing motor symptoms and improving quality of life [5]. The eMedica device's portability and ease of use make it an accessible tool for patients, complementing existing therapies and facilitating regular intervention [24-27].

Potential Benefits of eMedica in PD Management

Enhanced Motor Function

The modulation of electromagnetic frequencies may improve motor function through enhanced signal transmission in dopaminergic pathways, potentially mitigating the severity of bradykinesia and rigidity [5,11,14].

Neuroprotective Effects

eMedica could provide neuroprotective benefits by reducing oxidative stress and promoting neuronal repair processes. Such effects could slow disease progression and improve the longevity and efficacy of existing pharmacological treatments [19-20].

Improvement of Non-Motor Symptoms

Beyond motor symptoms, eMedica may address non-motor symptoms such as anxiety and depression through modulation of brain regions involved in mood regulation [1]. Improving the overall emotional well-being of patients is crucial for holistic PD management.

Figure1: The eMedica Device being used by the participants

Conclusion

PD poses significant challenges to affected individuals and healthcare providers. While traditional management strategies play an essential role, there is a continuous need for innovative therapeutic approaches. The eMedica electromagnetic frequency modulation device presents a promising adjunct to current therapies, demonstrating potential benefits in motor function, neuroprotection, and overall quality of life for PD patients. As research continues in this area, further clinical trials will be necessary to substantiate the efficacy and establish guidelines for the implementation of eMedica in comprehensive PD management.

References

1. Addante, R. J., Cummings, J. L., et al. (2021). The role of electrical stimulation in the management of non-motor symptoms of Parkinson's disease. *Neurotherapeutics*, 18, 100-108.

2. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May;20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2. PMID: 33894193; PMCID: PMC8185633.

3. Beauregard, O., et al. (2016). Cellular mechanisms of electromagnetic field effects on tissues. *BMC Complementary and Alternative Medicine*, 16(1), 1-22.

4. Pophof B, Henschenmacher B, Kattnig DR, Kuhne J, Vian A, Ziegelberger G. Biological Effects of Electric, Magnetic, and Electromagnetic Fields from 0 to 100 MHz on Fauna and Flora: Workshop Report. Health Phys. 2023 Jan 1;124(1):39-52. doi: 10.1097/HP.0000000000001624. Epub 2022 Nov 3. PMID: 36480584; PMCID: PMC9722389.

5. Hogan MK, Hamilton GF, Horner PJ. Neural Stimulation and Molecular Mechanisms of Plasticity and Regeneration: A Review. Front Cell Neurosci. 2020 Oct 14;14:271. doi: 10.3389/fncel.2020.00271. PMID: 33173465; PMCID: PMC7591397.

6. Vadalà M, Vallelunga A, Palmieri L, Palmieri B, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's disease. Behav Brain Funct. 2015 Sep 7;11:26. doi: 10.1186/s12993-015-0070-z. PMID: 26347217; PMCID: PMC4562205.

7. Sandyk R. Treatment with AC pulsed electromagnetic fields improves olfactory function in Parkinson's disease. Int J Neurosci. 1999 Apr;97(3-4):225-33. doi: 10.3109/00207459909000662. PMID: 10372649.

8. Consales C, Merla C, Marino C, Benassi B. The epigenetic component of the brain response to electromagnetic stimulation in Parkinson's Disease patients: A literature overview. Bioelectromagnetics. 2018 Jan;39(1):3-14. doi: 10.1002/bem.22083. Epub 2017 Oct 9. PMID: 28990199.

9. Hosseini SM, Farashi S, Bashirian S. Electromagnetic radiation therapy for Parkinson's disease tremor reduction- systematic reviews and Bayesian meta-analyses for comparing the effectiveness of electric, magnetic and light stimulation methods. J Neuroeng Rehabil. 2023 Sep 26;20(1):129. doi: 10.1186/s12984-023-01255-z. PMID: 37752553; PMCID: PMC10521577.

10. Sandyk R, Anninos PA, Tsagas N, Derpapas K. Magnetic fields in the treatment of Parkinson's disease. Int J Neurosci. 1992 Mar;63(1-2):141-50. doi: 10.3109/00207459208986664. PMID: 1342026.

11. Wang Z, Che PL, Du J, Ha B, Yarema KJ. Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PLoS One. 2010 Nov 8;5(11):e13883. doi: 10.1371/journal.pone.0013883. PMID: 21079735; PMCID: PMC2975637.

12. Dhillon K, Aizel K, Broomhall TJ, Secret E, Goodman T, Rotherham M, Telling N, Siaugue JM, Ménager C, Fresnais J, Coppey M, El Haj AJ, Gates MA. Directional control of neurite outgrowth: emerging technologies for Parkinson's disease using magnetic nanoparticles and magnetic field gradients. J R Soc Interface. 2022 Nov;19(196):20220576. doi: 10.1098/rsif.2022.0576. Epub 2022 Nov 9. PMID: 36349444; PMCID: PMC9653228.

13. Tan YY, Jenner P, Chen SD. Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future. J Parkinsons Dis. 2022;12(2):477-493. doi: 10.3233/JPD-212976. PMID: 34957948; PMCID: PMC8925102.

14. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan; 56(1):33-9. doi: 10.1001/archneur.56.1.33. PMID: 9923759.

15. Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2. Update in: Cochrane Database Syst Rev. 2024 Apr 08;4: CD013856. doi: 10.1002/14651858.CD013856.pub3. PMID: 36602886; PMCID: PMC9815433.

16. Morberg BM, Malling AS, Jensen BR, Gredal O, Bech P, Wermuth L. Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson's disease. Eur J Neurol. 2018 Jul;25(7):963-e74. doi: 10.1111/ene.13637. Epub 2018 Apr 17. PMID: 29573167.

17. Funk RHW, Fähnle M. A short review on the influence of magnetic fields on neurological diseases. Front Biosci (Schol Ed). 2021 Dec 3;13(2):181-189. doi: 10.52586/S561. PMID: 34879470.

18. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. PMID: 25904081.

19. Kulisevsky J. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. Rev Neurol. 2022 Oct 31;75(s04):S1-S10. English, Spanish. doi: 10.33588/rn.75s04.2022217. PMID: 36342310; PMCID: PMC10281635.

20. Nutt, J. G., & Wooten, G. F. (2005). Diagnosis and initial management of Parkinson's disease. *New England Journal of Medicine*, 353(2), 102-116.

21. Wyszkowska, Joanna & Jankowska, Milena & Gas, Piotr. (2019). Electromagnetic Fields and Neurodegenerative Diseases. Przeglad Elektrotechniczny. 95. 129-133. 10.15199/48.2019.01.33.

22. Yadav, R., et al. (2020). Neuroprotective effects of electromagnetic fields in neurodegenerative disorders: research and perspectives. *Neurological Sciences*, 41(6), 1795-1803.

23. Murat Terzi, Berra Ozberk, Omur Gulsum Deniz, Suleyman Kaplan, The role of electromagnetic fields in neurological disorders, Journal of Chemical Neuroanatomy, Volume 75, Part B, 2016, Pages 77-84, ISSN 0891-0618, https://doi.org/10.1016/j.jchemneu.2016.04.003.

24. Hemant Rohera, Dr Ramesh Chouhan, Dr. Mrunali Jambhulkar, Dr. Vaishali Khatri, & Dr. Deepak Nagpal. (2024). "Emedica: A Noninvasive Device to Improve Insulin Sensitivity in Type 2 Diabetes Patients". *Revista Electronica De Veterinaria*, *25*(1), 2469 - 2473. https://doi.org/10.69980/redvet.v25i1.1256

25. Dr Deepak Nagpal, Hemant Rohera. Evaluating the Efficacy of E-medica: A Cross-Sectional Analysis of Its Role in Hypertension Management. Afr. J. Biomed. Res. Vol. 27 (September2024); 1823-1827. DOI: https://doi.org/10.53555/AJBR.v27i1S.1721

26. Hemant Rohera, Dr Ramesh Chouhan , Dr Deepak Nagpal. Revolutionizing Osteoarthritis Management with eMedica micro-current therapy. NeuroQuantology, October 2024, Volume 22, Issue 5 ,174-178;doi: 10.48047/nq.2024.22.5.nq25018.

27. Dr Pratik Sheshrao Hande, Hemant Rohera, Dr. Gulam Saidunnisa Begum+, Dr Deepak Nagpal, Dr Srinivasa Gowda, Dr B K Manjunatha Goud. Enhancing Patient Outcomes with Emedica Technology in the Fight Against COVID-19: A Health and Medicine Approach. Afr. J. Biomed. Res. Vol. 27(September2024); 2861-2878. DOI:https://doi.org/10.53555/AJBR.v27i1S.1919.